Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics

Acta Histochemica

Volumn 114, Issue 2, 2012, Pages 131-139

  Narita, Diana ^a   Seclaman, Edward ^a   Ursoniu, Sorin ^a   Anghel, Andrei ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

ADAM12; ADAM17; Breast cancers; Gene expression; Laser capture microdissection

Indexed keywords

ADAM PROTEIN;

A DESINTEGRIN AND METALLOPROTEASE 12 GENE; A DESINTEGRIN AND METALLOPROTEASE 17 GENE; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CELL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; TUMOR GENE; UPREGULATION;

EID: 84856411132     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2011.03.009     Document Type: Article

References (48)

1. Arribas J., Bech-Serra J.J., Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev 2006, 25:57-68.
2. Atfi A., Dumont E., Colland F., Bonnier D., L'helgoualc'h A., Prunier C., et al. The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor. J Cell Biol 2007, 178:201-208.
3. Bierie B., Moses H.L. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520.
4. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells. Nature 1997, 385:729-733.
5. Blobel C.P., ADAM.S. key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005, 6:32-43.
6. Borrell-Pages M., Rojo F., Albanell J., Baselga J., Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003, 22:1114-1124.
7. De Kok J.B., Roelofs R.W., Giesendorf B.A., Pennings J.L., Waas E.T., Feuth T., Swinkels D.W., Span P.N. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005, 85:154-159.
8. Duffy M.J., McKiernan E., O'Donovan N., McGowan P. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009, 15:1140-1144.
9. Dyczynska E., Syta E., Sun D., Zolkiewska A. Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. Int J Cancer 2008, 122:2634-2640.
10. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol Aspects Med 2008, 29:258-289.
11. Emmert-Buck M.R., Bonner R.F., Smith P.D., Chuaqui R.F., Zhuang Z., Goldstein S.R., et al. Laser-capture microdissection. Science 1996, 274:998-1001.
12. Espina V., Wulfkuhle J.D., Calvert V.S., VanMeter A., Zhou W., Coukos G., et al. Laser-capture microdissection. Nat Protoc 2006, 2:586-602.
13. Fridman J.S., Caulder E., Hansbury M. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 2007, 13:1892-1902.
14. Fröhlich C., Albrechtsen R., Dyrskjot L., Rudkjaer L., Ørntoft T.F., Wewer U.M. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 2006, 12:7359-7368.
15. Horiuchi K., Le Gall S., Schulte M., Yamaguchi T., Reiss K., Murphy G., et al. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 2007, 18:176-188.
16. Iba K., Albrechtsen R., Gilpin B., Fröhlich C., Loechel F., Zolkiewska A., et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading. J Cell Biol 2000, 149:1143-1156.
17. Jacobsen J., Wewer U.M. Targeting ADAM12 in human disease: head, body or tail?. Curr Pharm Des 2009, 15:2300-2310.
18. Kawaguchi N., Horiuchi K., Becherer J.D., Toyama Y., Besmer P., Blobel C.P. Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19. J Cell Sci 2007, 120:943-952.
19. Kodama T., Ikeda E., Okada A., Ohtsuka T., Shimoda M., Shiomi T., et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 2004, 165:1743-1753.
20. Kuefer R., Day K.C., Kleer C.G., Sabel M.S., Hofer M.D., Varambally S., et al. ADAM15 disintegrin is associated with aggressive prostate and breast cancer diseases. Neoplasia 2006, 8:319-329.
21. Kveiborg M., Albrechtsen R., Couchman J.R., Wewer U.M. Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol 2008, 40:1685-1702.
22. Kveiborg M., Fröhlich C., Albrechtsen R., Tischler V., Dietrich N., Holck P., et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 2005, 65:4754-4760.
23. Laigaard J., Sørensen T., Fröhlich C., Pedersen B.N., Christiansen M., Schiøtt K., et al. ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 2003, 23:1086-1091.
24. Le Pabic H., Bonnier D., Wewer U.M., Coutand A., Musso O., Baffet G., et al. ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003, 37:1056-1066.
25. Lendeckel U., Kohl J., Arndt M., Carl-McGrath S., Donat H., Röcken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 2005, 31:41-48.
26. Liu X., Fridman J.S., Wang Q., Caulder E., Yang G., Covington M., et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentates the anti-tumor effects of trastuzumab. Cancer Biol Ther 2006, 5:648-656.
27. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001, 25:402-408.
28. Lu X., Lu D., Scully M., Kakkar V. ADAM proteins - therapeutic potential in cancer. Curr Cancer Drug Targets 2008, 8:720-732.
29. McGowan P.M., McKiernan E., Bolster F., Ryan B.M., Hill A.D., McDermott E.W., et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 2008, 19:1075-1081.
30. Mochizuki A., Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007, 98:621-628.
31. Murphy G., The ADAMs: signaling scissors in the tumor microenvironment. Nat Rev Cancer 2008, 8:929-941.
32. Narita D., Anghel A., Seclaman E., Ilina R., Cireap N., Ursoniu S. Molecular profiling of ADAM12 gene in breast cancers. Rom J Morphol Embryol 2010, 51:669-676.
33. Niimi H., Pardali K., Vanlandewijck M., Heldin C.H., Moustakas A. Notch signaling is necessary for epithelial growth arrest by TGF-β. J Cell Biol 2007, 176:695-707.
34. Ohtsu H., Dempsey P.J., Eguchi S. ADAMs as mediators of EGF receptor transactivation by G-protein-coupled receptors. Am J Physiol Cell Physiol 2006, 291:C1-C10.
35. O'Shea C., McKie N., Buggy Y., Duggan C., Hill A.D., McDermott E., et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003, 105:754-761.
36. Peduto L., Reuter V.E., Sehara-Fujisawa A., Shaffer D.R., Scher H.I., Blobel C.P., et al. ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene 2006, 25:5462-5466.
37. Peschon J.J., Slack J.L., Reddy P., Stocking K.L., Sunnarborg S.W., Lee D.C., et al. An essential role for ectodomain shedding in mammalian development. Science 1998, 282:1281-1284.
38. Pories S., Zurakowski D., Roy R., Lamb C.C., Raza S., Exarhopoulos A., et al. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008, 17:1034-1042.
39. Rocks N., Paulissen G., Calvo F.Q., Polette M., Gueders M., Munaut C., et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer 2006, 94:724-730.
40. Roy R., Wewer M.U., Zurakowski D., Pories E.S., Moses M.A. ADAM12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004, 49:51323-51330.
41. Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003, 17:7-30.
42. Shi Z., Xu W., Loechel F., Wewer U.M., Murphy L.J. ADAM12, a disintegrin and metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000, 275:18574-18580.
43. Sorensen H.P., Vives R.R., Manetopoulos C., Albrechtsen R., Lydolph M.C., Jacobsen J., et al. Heparan sulfate regulates ADAM12 through a molecular switch mechanism. J Biol Chem 2008, 46:31920-31932.
44. Turashvili G., Bouchal J., Baumforth K., Wei W., Dziechciarkova M., Ehrmann J., et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007, 7:55-75.
45. Wewer U.M., Mörgelin M., Holck P., Jacobsen J., Lydolph M.C., Johnsen A.H., et al. ADAM12 is a four-leafed clover. The excised prodomain remains bound to the mature enzyme. J Biol Chem 2006, 281:9418-9422.
46. Zheng Y., Saftig P., Hartmann D., Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor α (TNF α) shedding and of the function of the TNF α ectodomain in ensuring selective stimulated shedding by the TNF α convertase (TACE/ADAM17). J Biol Chem 2004, 41:42898-42906.
47. Zhou B.B., Petyon M., He B., Liu C., Girard L., Caudler E., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER2 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006, 10:39-50.
48. Zucker S., Cao J., Chen W.T. Critical appraisal of the use of matrix metalloproteinases inhibitors in cancer treatment. Oncogene 2000, 19:6642-6650.